Can a daily pill keep leftover lung spots from turning into cancer?
NCT ID NCT05528458
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug osimertinib can stop or shrink small, hazy lung spots (called ground-glass nodules) that remain after surgery for a type of lung cancer. About 59 adults with EGFR-mutant lung adenocarcinoma will take one pill daily. The goal is to see if the drug prevents these spots from growing into active cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sehoon Lee
RECRUITINGSeoul, 06351, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI be a Pathologist's second opinion?
- Blood tests could unlock early clues for three major lung diseases
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
- Why some Never-Smokers get lung cancer: a new study investigates
- Could an asthma drug help fight lung cancer? early trial investigates
- Vaccine trains immune system to hunt down cancer cells